SA519402288B1 - مركب بيريميدين واستخداماته الصيدلانية - Google Patents

مركب بيريميدين واستخداماته الصيدلانية

Info

Publication number
SA519402288B1
SA519402288B1 SA519402288A SA519402288A SA519402288B1 SA 519402288 B1 SA519402288 B1 SA 519402288B1 SA 519402288 A SA519402288 A SA 519402288A SA 519402288 A SA519402288 A SA 519402288A SA 519402288 B1 SA519402288 B1 SA 519402288B1
Authority
SA
Saudi Arabia
Prior art keywords
pyrimidine compound
pharmaceutical use
pyrimidine
cancer
prevention
Prior art date
Application number
SA519402288A
Other languages
English (en)
Inventor
يونج جيل اهن،
ان هوان باى،
كوى هيون سوه،
جاى يول شوى
سيوك جونج كانج،
تاى وو كيم،
سيو هى كيم،
يونج جين هام،
Original Assignee
هانمى فارم كو. ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by هانمى فارم كو. ليمتد filed Critical هانمى فارم كو. ليمتد
Publication of SA519402288B1 publication Critical patent/SA519402288B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

يتعلق الاختراع الحالي بتقديم مركب بيريميدين pyrimidine compound ممثل بالصيغة 1، طريقة لتحضيره، واستخدام صيدلاني لمركب البيريميدين للوقاية من أو معالجة السرطان.
SA519402288A 2017-01-26 2019-07-24 مركب بيريميدين واستخداماته الصيدلانية SA519402288B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170012766 2017-01-26
PCT/KR2018/001193 WO2018139903A1 (ko) 2017-01-26 2018-01-26 피리미딘 화합물 및 그의 의약 용도

Publications (1)

Publication Number Publication Date
SA519402288B1 true SA519402288B1 (ar) 2022-03-09

Family

ID=62979563

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519402288A SA519402288B1 (ar) 2017-01-26 2019-07-24 مركب بيريميدين واستخداماته الصيدلانية

Country Status (23)

Country Link
US (2) US10280154B2 (ar)
EP (2) EP3514153B1 (ar)
JP (3) JP6608565B2 (ar)
KR (1) KR101954369B1 (ar)
CN (1) CN110214138A (ar)
AR (1) AR110778A1 (ar)
AU (1) AU2018211880B2 (ar)
BR (1) BR112019015256A2 (ar)
CA (1) CA3050239A1 (ar)
DK (1) DK3514153T3 (ar)
EA (1) EA039868B1 (ar)
ES (1) ES2890668T3 (ar)
HU (1) HUE056472T2 (ar)
IL (2) IL290745B2 (ar)
MX (1) MX2019008808A (ar)
PH (1) PH12019501690A1 (ar)
PL (1) PL3514153T3 (ar)
PT (1) PT3514153T (ar)
SA (1) SA519402288B1 (ar)
SG (1) SG11201906435SA (ar)
TW (1) TWI810172B (ar)
WO (1) WO2018139903A1 (ar)
ZA (1) ZA201905020B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008808A (es) * 2017-01-26 2019-09-16 Hanmi Pharma Co Ltd Compuesto de pirimidina y su uso farmaceutico.
AU2019203034B1 (en) * 2018-07-25 2019-09-26 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
MX2021010115A (es) 2019-02-22 2021-09-21 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
WO2020171649A1 (ko) * 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
AU2020226111A1 (en) * 2019-02-22 2021-09-09 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
CN111606889B (zh) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
JP2022538817A (ja) 2019-06-27 2022-09-06 ハンミ ファーマシューティカル カンパニー リミテッド Ｆｌｔ３阻害剤および化学療法剤を含む急性骨髄白血病を治療するための薬学的組成物
US20240092763A1 (en) * 2021-01-07 2024-03-21 Ontario Institute For Cancer Research (Oicr) Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
WO2023082052A1 (zh) * 2021-11-09 2023-05-19 暨南大学 环状2-氨基嘧啶类化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
TW201022262A (en) * 2008-10-29 2010-06-16 Astrazeneca Ab Novel compounds 515
US20110005173A1 (en) * 2009-07-08 2011-01-13 Kraft Foods Global Brands Llc Method and Apparatus to Create a Contoured Flow Wrap Package
MX2012000709A (es) * 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopiridina de cinasas.
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
CN103702990B (zh) 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
SG11201608242XA (en) * 2014-04-04 2016-10-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016029839A1 (zh) * 2014-08-25 2016-03-03 四川海思科制药有限公司 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途
RS63981B1 (sr) * 2017-01-17 2023-03-31 Astrazeneca Ab Selektivni inhibitori jak1
MX2019008808A (es) * 2017-01-26 2019-09-16 Hanmi Pharma Co Ltd Compuesto de pirimidina y su uso farmaceutico.

Also Published As

Publication number Publication date
JP7191799B2 (ja) 2022-12-19
ZA201905020B (en) 2020-12-23
EA201991580A1 (ru) 2020-02-03
SG11201906435SA (en) 2019-08-27
WO2018139903A1 (ko) 2018-08-02
IL290745B2 (en) 2023-11-01
ES2890668T3 (es) 2022-01-21
CA3050239A1 (en) 2018-08-02
DK3514153T3 (da) 2021-09-27
US10519141B2 (en) 2019-12-31
EP3514153B1 (en) 2021-07-07
US20190127353A1 (en) 2019-05-02
EA039868B1 (ru) 2022-03-22
HUE056472T2 (hu) 2022-02-28
JP6608565B2 (ja) 2019-11-20
KR101954369B1 (ko) 2019-03-05
TW201829396A (zh) 2018-08-16
IL290745B1 (en) 2023-07-01
JP2019531315A (ja) 2019-10-31
EP3514153A4 (en) 2020-04-29
AU2018211880B2 (en) 2019-04-11
JP2020023554A (ja) 2020-02-13
EP3789386A1 (en) 2021-03-10
AR110778A1 (es) 2019-05-02
US20190031643A1 (en) 2019-01-31
IL290745A (en) 2022-04-01
US10280154B2 (en) 2019-05-07
AU2018211880A1 (en) 2018-09-13
TWI810172B (zh) 2023-08-01
MX2019008808A (es) 2019-09-16
JP2023027203A (ja) 2023-03-01
IL268010B (en) 2022-04-01
PT3514153T (pt) 2021-09-22
KR20180088317A (ko) 2018-08-03
CN110214138A (zh) 2019-09-06
BR112019015256A2 (pt) 2020-04-14
PL3514153T3 (pl) 2022-01-17
IL268010A (en) 2019-09-26
EP3514153A1 (en) 2019-07-24
PH12019501690A1 (en) 2020-03-09

Similar Documents

Publication Publication Date Title
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MY194116A (en) Pharmaceutical compounds
PH12019501955A1 (en) Tri-cycle compound and applications thereof
TN2019000211A1 (en) Antitumoral compounds
PH12019500196A1 (en) Compounds and compositions and uses thereof
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2016010877A (es) Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
WO2018211324A8 (en) Prodrugs for the treatment of disease
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
TWI839363B (zh) 嘧啶化合物及包括其之供預防或治療癌症的藥學組成物
PH12018501100A1 (en) Phenylimidazole compound
MX2019005504A (es) Potenciadores de bmp.
MX2019005090A (es) Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc).
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease